Results 21 to 30 of about 125,098 (310)

Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels [PDF]

, 2003
The impact of common variants in the apolipoprotein gene cluster (APOC3-A4-A5) on prospective coronary heart disease (CHD) risk was examined in healthy UK men. Of the 2808 men followed over 9 years, 187 had a clinically defined CHD event.
Hawe, E., Miller, G.J., Hawe, Emma, Nicaud, V., Wong, W.-M.R., Wong, Wai-man R., Humphries, S.E., Li, Lai K., Li, L.K., Talmud, P.J., Nicaud, Viviane, Miller, George J., Pennacchio, Len A., Talmud, Philippa J., Pennacchio, L.A., Humphries, Steve E.   +15 more
core   +1 more source

Effect of Early Enteral Feeding on Apolipoprotein AI Levels and High-Density Lipoprotein Heterogeneity in Preterm Infants [PDF]

, 2001
Background/Aim: We have previously shown that infants receiving total parenteral nutrition have low apolipoprotein Al levels which are associated with high-density lipoprotein (HDL) class distributions as in lecithin:cholesterol acyltransferase ...
Berthold Koletzkob, Koletzko, Berthold, Yvonne Göbelb, Genzel-Boroviczény, Orsolya, Göbel, Yvonne, Orsolya Genzel-boroviczénya   +5 more
core   +1 more source

An Apolipoprotein A-I Mimetic Works Best in the Presence of Apolipoprotein A-I [PDF]

Circulation Research, 2005
See related article, pages 1190–1197 Ou et al1 report that an apolipoprotein A-I (apoA-I) mimetic peptide, D-4F, reduced wall thickness and improved vasoreactivity in the fascialis artery (internal diameter 180 to 240 μm) in low-density lipoprotein (LDL) receptor–null mice on a Western diet.
Mohamad Navab, G.M. Anantharamaiah, Alan M. Fogelman   +2 more
openaire   +1 more source

Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix [PDF]

Hepatology, 1996
Apolipoprotein A-I (Apo A-I), a protein produced mainly by hepatocytes, is decreased in the sera of alcoholic patients with liver fibrosis and cirrhosis. To explain this decrease, we investigated possible interactions between liver extracellular matrix (ECM) and Apo A-I.
V, Paradis, P, Mathurin, V, Ratziu, T, Poynard, P, Bedossa   +4 more
openaire   +3 more sources

Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes1

Journal of Lipid Research, 2006
Plasma cholesteryl ester transfer protein (CETP) has a profound effect on neutral lipid transfers between HDLs and apolipoprotein B (apoB)-containing lipoproteins when it is expressed in combination with human apoA-I in HuAI/CETP transgenic (Tg) rodents.
David Masson, Jean-Paul Pais de Barros, Zoulika Zak, Thomas Gautier, Naig Le Guern, Mahfoud Assem, Jeffrey W. Chisholm, James R. Paterniti, Jr., Laurent Lagrost   +8 more
doaj   +1 more source

Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT

Journal of Lipid Research, 2001
We have previously identified a single amino acid mutation (hE149A) in human LCAT that increases its in vitro reactivity with phosphatidylcholine species containing sn-2 arachidonate (Wang et al. 1997. J. Biol. Chem. 272: 280–286).
James W. Furbee, Jr., Omar Francone, John S. Parks   +2 more
doaj   +1 more source

Apolipoprotein A‐I: the dual face of a protein [PDF]

FEBS Letters, 2016
Conformational plasticity and flexibility are key structural features of ApoAI in lipid metabolism. Amyloidogenic single point mutations, associated with incurable familial amyloidosis with fibril deposition in peripheral organs, may have a dramatic impact on the structural and functional features of ApoAI.
ARCIELLO, ANGELA, PICCOLI, RENATA, MONTI, DARIA MARIA   +2 more
openaire   +3 more sources

A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes

Journal of Lipid Research, 2005
The exchangeable apolipoproteins present in small, dense LDL (sdLDL) and large, buoyant LDL subclasses were evaluated with a quantitative proteomic approach in patients with the metabolic syndrome and with type 2 diabetes, both with subclinical ...
Pia Davidsson, Johannes Hulthe, Björn Fagerberg, Britt-Marie Olsson, Carina Hallberg, Björn Dahllöf, Germán Camejo   +6 more
doaj   +1 more source

Probing the Structure–Function relationship and amyloidogenic propensities in natural variants of apolipoprotein A-I

Biochemistry and Biophysics Reports, 2020
Background: Apolipoprotein A-I (apoA-I) protects against atherosclerosis and participates in the removal of excess cellular cholesterol from peripheral organs. Several naturally occurring apoA-I mutations are associated with familial systemic amyloidosis,
Farah Ma'arfi, Subhash Chandra Prasad, Jamal e Fatima, Mohd Yasir Khan, Snober S. Mir, Mohd Aslam Yusuf   +5 more
doaj   +1 more source

Importance of Apolipoprotein A-I in Multiple Sclerosis [PDF]

Frontiers in Pharmacology, 2015
Jean-Martin Charcot has first described multiple sclerosis (MS) as a disease of the central nervous system (CNS) over a century ago. MS remains incurable today, and treatment options are limited to disease modifying drugs. Over the years, significant advances in understanding disease pathology have been made in autoimmune and neurodegenerative ...
Lidia A Gardner, Lidia A Gardner, Michael C Levin, Michael C Levin, Michael C Levin   +4 more
openaire   +5 more sources